SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Clinical trials for SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA trials appear
Sign up with your email to follow new studies for SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail targets Hard-to-Treat brain lymphoma
Disease control Recruiting nowThis early-phase study tests whether combining two drugs, epcoritamab and ibrutinib, is safe for people whose central nervous system lymphoma has come back or not responded to treatment. About 26 adults with this rare cancer will receive the drug combination. The main goal is to …
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New antibody combo aims to treat brain lymphoma
Disease control Recruiting nowThis trial investigates a combination of two drugs—tafasitamab, an antibody given by IV, and lenalidomide, an oral medication—for people with relapsed central nervous system (CNS) lymphoma. The study includes up to 35 participants and is the first to test this antibody in CNS lym…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: James Rubenstein • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New cell therapy takes on hard-to-treat brain lymphoma in early trial
Disease control Recruiting nowThis early-phase study tests a personalized cell therapy called MB-CART19.1 for people with central nervous system lymphoma (CNSL) that has returned or not responded to prior treatments. The therapy uses the patient's own immune cells, modified to attack the cancer, and is made o…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New pill aims to stop High-Risk lymphoma relapse after cell treatment
Disease control Recruiting nowThis study tests whether the drug acalabrutinib, taken as a pill, can safely prevent relapse in people with very high-risk large B-cell lymphoma after they receive cell therapy (stem cell transplant or CAR T-cells). The trial will enroll 24 adults aged 18-70. Researchers will tra…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo aims to tackle recurrent brain lymphomas
Disease control Recruiting nowThis phase 2 trial is testing whether a combination of two drugs, zanubrutinib and pemetrexed, can safely control or shrink brain lymphomas that have come back or not responded to treatment. About 15 participants will receive the drugs in cycles, followed by maintenance therapy w…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE2 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Brain Radiation's hidden toll: new study tracks memory loss in blood cancer survivors
Knowledge-focused Recruiting nowThis study follows 100 adults with blood cancers (like lymphoma or leukemia) who receive whole brain radiation. Researchers will test memory, thinking, and quality of life over time using MRI scans and questionnaires. The goal is to understand how radiation affects the brain, not…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC